The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.
 
Jamie E. Chaft
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Merck
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
 
Daniel Botelho Costa
Honoraria - Pfizer; Takeda/Millennium
Consulting or Advisory Role - AstraZeneca; Takeda/Millennium
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech (Inst); Merck (Inst); Merrimack (Inst); Pfizer (Inst); Takeda/Millennium (Inst)
 
Alona Muzikansky
Consulting or Advisory Role - Sofregen
 
Joseph B Shrager
Consulting or Advisory Role - Becton Dickinson
Research Funding - Varian Medical Systems
Patents, Royalties, Other Intellectual Property - 2 Patents - a potential pharmacological means of preventing ventilator-induced diaphragm dysfunction -a potential use of CRISPR for EGFR mutant lung cancer therapy
 
Michael Lanuti
Honoraria - Emory University; Holy Cross Hospital
Research Funding - NIH; NIH; Stand up to Cancer
 
James Huang
No Relationships to Disclose
 
Kavitha Ramchandran
No Relationships to Disclose
 
Deepa Rangachari
Consulting or Advisory Role - Advance Medical; DynaMed
 
Mark Huberman
No Relationships to Disclose
 
Zofia Piotrowska
Consulting or Advisory Role - Abbvie; ARIAD/Takeda; AstraZeneca; Guardant Health; Immunogen; Immunogen; Novartis; Spectrum Pharmaceuticals
Research Funding - ARIAD/Takeda (Inst); AstraZeneca (Inst); Guardant Health (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - ARIAD/Takeda; AstraZeneca
 
Mark G. Kris
Consulting or Advisory Role - AstraZeneca; Pfizer; Regeneron
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - Memorial Sloan-Kettering Cancer Center
 
Christopher G. Azzoli
Consulting or Advisory Role - ARIAD/Takeda; Merck
 
Lecia V. Sequist
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Genentech/Roche; Merrimack; Pfizer
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Genentech (Inst); Guardant Health (Inst); Incyte (Inst); Johnson & Johnson (Inst); Loxo (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Pfizer (Inst)
 
Joel W. Neal
Consulting or Advisory Role - ARIAD/Takeda; AstraZeneca; Exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Loxo
Research Funding - ARIAD/Takeda (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst)